MetaCap

Immunome (IMNM) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zymeworks (ZYME) has outperformed Immunome (IMNM) over the past year, gaining 8.8% versus a loss of 15.3%. Over five years, ZYME leads with a +34.1% price change compared with -7.5% for IMNM. Immunome is the larger company by market cap ($1.85 billion vs $1.81 billion), about 1.0 times the size, while Zymeworks is growing revenue faster (+38.9% vs -23.2%).

Zymeworks converts more of its revenue into profit, with a net margin of -76.6% versus -3060.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNM-15.33%ZYME+8.83%
+65%+23%-19%
Nov 21, 20251 yearNov 20, 2026
IMNM-8.78%ZYME+31.95%
+73%-11%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNM versus ZYME key metrics
MetricIMNMZYME
Share price$15.69$26.14
Market cap$1.85B$1.81B
1-day change-5.54%-2.68%
YTD return-26.96%-0.72%
1-year return-15.33%+8.83%
5-year return-7.54%+34.05%
P/E ratio (TTM)—49.32
Forward P/E—54.95
EPS (TTM)$-2.63$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.94M$105.97M
Revenue growth (YoY)-23.23%+38.87%
Net income (latest FY)$-212.39M$-81.13M
Operating margin-3228.83%-87.34%
Net margin-3059.99%-76.56%
52-week high$30.06$31.97
52-week low$15.55$21.52
Distance from 52-week high-47.80%-18.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+123.90%+65.61%
Average volume1.36M1.09M
Shares outstanding118.07M68.70M
Employees267279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZYME has outperformed IMNM by 24.2 percentage points over the past year.
  • Zymeworks is more profitable, keeping -76.6 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
  • Zymeworks grew revenue faster in its latest fiscal year (+38.87% vs -23.23%).

About Immunome

IMNM stock →

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

IMNM vs ZYME FAQ

Which is bigger, Immunome or Zymeworks?

Immunome (IMNM) is larger, with a market capitalization of $1.85B compared with $1.81B for Zymeworks (ZYME).

Which stock has performed better over the past year, IMNM or ZYME?

ZYME returned +8.83% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.

Are Immunome and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons